In this study, BRAF + MEK blockade was superior to second‐line adjuvant PD‐1 treatment in BRAF(V600E) mutant melanoma (HR 0.192 (0.05–0.731), p = 0.016) (Figure 2a). The gene discussed is BRAF; the disease is melanoma.